Delegates can now secure their place at http://www.haagstreituk.com/retinasymposium . HS-UK Retina Symposium 2017 Faculty Harlow, Essex (PRWEB UK) 27 October 2016 Haag-Streit UK (HS-UK), the leading manufacturer and distributor of gold-standard optometry and ophthalmic equipment, is delighted to confirm that online booking is now live for the upcoming HS-UK Retina Symposium 2017. Delegates can now secure their place at http://www.haagstreituk.com/retinasymposium . Dr Pearse A. Keane, Moorfields Eye Hospital, will be chairing the Symposium. The Keynote Lecture Why 2RT? 50 Years of Science will be delivered by Prof John Marshall MBE, Professor of Ophthalmology, Institute of Ophthalmology. Other confirmed members of the Faculty include; Prof Giovanni Staurenghi, University of Milan Dr Michel Puech, Ophthalmologist, VuExpolora Institute of Paris Ms Rehna Khan, Consultant Ophthalmologist, Calderdale Hospitals NHS Trust Mr Nishal Patel, Consultant Ophthalmic Surgeon, Kent & Canterbury Hospital Mr Marco Morales, Ophthalmology & Visual Science Nottingham University Mr Serge Pierrache, International Sales Director, EMEA Optovue. The Symposium will cover a variety of topics, including; OCT angiography (OCT-A), including its use in diabetic retinopathy DMO and AMD SLO microperimetry Wide-field, true colour and auto-fluorescence imaging. It will be held at the historic Midland Hotel in Manchester on 30th January 2017.try this out
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2016/10/prweb13801767.htm
Some may experience blurring while some may experience complete blindness. Reversing the damage or vision correction is very difficult. http://youtube.com/watch?feature=youtube_gdata&v=0oSq1pQv9Vohttp://bravemiajordan.prosportsmall.com/2016/11/03/the-fundamentals-of-elementary-solutions-in-eye-surgery-in-london/It is a fact that cells that form the optic nerve are unable to regenerate, or they cannot repair themselves. Therefore, optic nerve damage from glaucoma and other diseases or trauma is irreversible. Other common diseases like diabetes, pernicious anaemia and hyperthyroidism, direct trauma to the optic nerve, nutritional deficiencies, and exposure to toxins like lead, methyl alcohol, quinine, and arsenic may also result in damaged optic nerve. It carries visual information from the retina to the brain. Inflammation of the spinal cord and optic nerve, known as neuromyelitis optic. is an autoimmune disorder, which can affect the function of the nerves. The condition wherein the optic nerve is inflamed is called ‘optic neuritis'; which if not treated promptly, can lead to loss of vision.
Here we present a new approach to PDT treatment of bladder cancer using instillation of a novel water soluble ruthenium-based PS, known as TLD-1433 and the TLC-3200 (Theralase Inc., Toronto, Canada) laser and dosimetry system that was designed to emit and detect 525 nm laser light in the bladder. Confocal microscope cellular uptake studies of TLD-1433 demonstrate that TLD-1433 is primarily localized in the cellular cytoplasm. Inductively Coupled Plasma – Mass Spectrometry (“ICP-MS”) studies of tissue uptake after systemic injection in mice showed clearance within 24 hours from most tissue, while one hour TLD-1433 intravesical instillation into the rat bladder demonstrated minimal seepage into systemic circulation. Tumour versus normal urothelium uptake of TLD-1433 was measured in the orthotopic rat bladder model and preferential tumour uptake was observed (186x preferential uptake in bladder tumour versus normal urothelium). Confirmatory preclinical studies utilizing “TLD-1433 only” or “Laser light only” treatments demonstrated no discernible effects on tumor growth rate, normal urothelium or bladder musculature. After 90 J/cm2 525 nm PDT treatment with TLD-1433, full depth tumor necrosis was observed at both 0.6 and 6.0 mg/mL instillation concentrations in the majority of tumours. Muscle invasive tumors were also destroyed by the PDT treatment to a depth of over 1 mm, while normal bladder muscle tissue was unaffected after PDT treatment. The urothelium showed local inflammation near the tumour that was beginning to resolve 48 hours post PDT, demonstrating the localized PDT effect to bladder cancer tumours only. To establish the clinical safety of TLD-1433, GLP toxicology, pharmacodynamics and pharmacokinetics studies were performed in rat and dog models. The No Observed Adverse Effect Level (“NOAEL”) dose in the systemic rat model was determined to be 6 mg/kg. No effects on body weight, food consumption, clinical pathology, ophthalmology, organ weight or macroscopic/microscopic observations were noted.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/theralase-anti-cancer-technology-presented-110000099.html